Page last updated: 2024-09-04

carbapenems and Pneumonia, Staphylococcal

carbapenems has been researched along with Pneumonia, Staphylococcal in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Kurihara, S; Morinaga, Y; Nakamura, S; Ohnishi, Y; Seki, M; Yamada, Y; Yamamoto, Y; Yanagihara, K1
Koulenti, D; Rello, J1
Araki, N; Izumikawa, K; Kakeya, H; Kamihira, S; Kihara, R; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Tsukamoto, K; Yamamoto, Y; Yanagihara, K1
Abe, T; Domon, H; Fukuoka, T; Harasaki, T; Hirasawa, A; Ishii, C; Iwata, M; Kakuta, M; Kawada, H; Koga, T; Kubota, M; Kuwahara, S; Masuda, N; Ohya, S; Sakagawa, E; Takenouchi, T; Utsui, Y; Yasuda, H1

Reviews

1 review(s) available for carbapenems and Pneumonia, Staphylococcal

ArticleYear
Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:12

    Topics: Acinetobacter Infections; Administration, Inhalation; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Methicillin Resistance; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Practice Guidelines as Topic; Pseudomonas Infections; Respiration, Artificial; Vancomycin

2006

Other Studies

3 other study(ies) available for carbapenems and Pneumonia, Staphylococcal

ArticleYear
Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.
    International journal of antimicrobial agents, 2008, Volume: 32, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Blood-Borne Pathogens; Carbapenems; Lung; Methicillin-Resistant Staphylococcus aureus; Mice; Pneumonia, Staphylococcal; Staphylococcus aureus; Tissue Distribution; Vancomycin; Vancomycin Resistance

2008
Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6

    Topics: Animals; Anti-Bacterial Agents; Blood-Borne Pathogens; Bronchopneumonia; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Humans; Lung; Male; Methicillin Resistance; Mice; Pneumonia, Staphylococcal; Specific Pathogen-Free Organisms; Staphylococcus aureus; Treatment Outcome; Vancomycin; Vancomycin Resistance

2008
In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:12

    Topics: Administration, Oral; Animals; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Carbapenems; Carrier Proteins; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Drug Stability; Hexosyltransferases; Imipenem; Mice; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Pneumonia, Staphylococcal; Prodrugs; Thienamycins

1997